These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 21056013)
1. Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease. Small G; Bullock R Alzheimers Dement; 2011 Mar; 7(2):177-84. PubMed ID: 21056013 [TBL] [Abstract][Full Text] [Related]
2. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561 [TBL] [Abstract][Full Text] [Related]
3. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Beier MT Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151 [TBL] [Abstract][Full Text] [Related]
4. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council. Fillit H; Cummings J Manag Care Interface; 2000 Jan; 13(1):51-6. PubMed ID: 10747691 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of Alzheimer's disease utilising the best available evidence-based medicine -- utopia?]. Stoppe G; Pirk O; Haupt M Gesundheitswesen; 2005 Jan; 67(1):20-6. PubMed ID: 15672302 [TBL] [Abstract][Full Text] [Related]
12. The treatment of Alzheimer's disease: the approach from a clinical specialist in the trenches. Hake AM Semin Neurol; 2002 Mar; 22(1):71-4. PubMed ID: 12170395 [TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Darreh-Shori T; Jelic V Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294 [TBL] [Abstract][Full Text] [Related]
14. Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease. Prescrire Int; 2001 Dec; 10(56):180-1. PubMed ID: 11824442 [TBL] [Abstract][Full Text] [Related]
15. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease. Haywood WM; Mukaetova-Ladinska EB Am J Geriatr Pharmacother; 2006 Sep; 4(3):273-86. PubMed ID: 17062329 [TBL] [Abstract][Full Text] [Related]
19. Increasing rational use of cholinesterase inhibitors for Alzheimer's disease in Brazil: public health strategy combining guideline with peer-review of prescriptions. Picon PD; Camozzato AL; Lapporte EA; Picon RV; Moser Filho H; Cerveira MO; Chaves ML Int J Technol Assess Health Care; 2010 Apr; 26(2):205-10. PubMed ID: 20392325 [TBL] [Abstract][Full Text] [Related]
20. Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease. Ballard C; Corbett A; Sharp S Expert Rev Neurother; 2011 Mar; 11(3):327-9. PubMed ID: 21375436 [No Abstract] [Full Text] [Related] [Next] [New Search]